Skip to main content

Recombinant Human LBP (Histidine-tagged) Protein

R&D Systems, part of Bio-Techne | Catalog # 6445-LP

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
Carrier Free
6445-LP-025/CF

Catalog #
Availability
Size / Price
Qty
With Carrier
6445-LP-025

Key Product Details

Source

NS0

Accession #

Structure / Form

Monomer

Conjugate

Unconjugated

Applications

Bioactivity

Product Specifications

Source

Mouse myeloma cell line, NS0-derived human LBP protein
Ala26-Val481 with a C-terminal 6-His tag

Purity

>95%, by SDS-PAGE under reducing conditions and visualized by silver stain.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Ala26

Predicted Molecular Mass

51.7 kDa

SDS-PAGE

60-65 kDa, reducing conditions

Activity

Measured by its ability to enhance LPS-stimulated IL-8 secretion by THP-1 human acute monocytic leukemia cells.
The ED50 for this effect is 0.25-1.5 ng/mL.

Formulation, Preparation and Storage

Carrier Free
What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

Carrier: 6445-LP
Formulation Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
Reconstitution Reconstitute at 100 μg/mL in PBS containing at least 0.1% human or bovine serum albumin.
Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Carrier Free: 6445-LP/CF
Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution Reconstitute at 100 μg/mL in PBS.
Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: LBP

LBP (Lipopolysaccharide binding protein) is a 58 ‑ 62 kDa, glycoprotein member of the BPI/LBP family of lipid-binding proteins (1 ‑ 4). It is secreted by hepatocytes, gingival keratinocytes, intestinal paneth cells, type II Greater alveolar cells, lacrimal and submandibular gland epithelium, and caudal epididymal epithelium (5 - 10). LBP is a class 1 APR (acute phase reactant) that is induced upon exposure to both IL-1 and IL-6 (11). Following its synthesis and release, LBP interacts with bacterial wall components, lipopolysaccharide/LPS/Lipid A from Gram- (Gm-) bacteria, and lipoteichoic acid/LTA from Gm+ bacteria (12 ‑ 16). In the case of LPS, this interaction occurs both in the bacterial cell wall, and within the intercellular space, where LPS micelles naturally form following bacterial death and cell wall dissolution (17 ‑ 20). LBP induces disassembly of LPS micelles, allowing for LPS binding to LBP, and a heparin-mediated transfer of LPS from LBP to membrane-bound CD14 on the surface of monocytes/macrophages (18, 21). This CD14:LPS complex activates a TLR4:MD2 membrane complex, resulting in the production of NO and TNF alpha (22). TNF alpha serves as a chemoattractant for PMNs, and an initiator of coagulation that helps to wall-off and localize microbial elements (19). In addition to the above, LBP is also reported to transfer LPS to lipoproteins, particularly HDL and LDL (22 ‑ 25). For LDL, this transfer inhibits monocyte activation; for HDL, the effect may be either stimulatory or inhibitory, depending upon the circumstances (22). Human LBP is synthesized as a 481 amino acids (aa) precursor that contains a 25 aa signal sequence and a 456 aa mature region (aa 26 ‑ 481) (26). It contains an N-terminal LPS binding region (aa 29 ‑ 252) plus a likely C-terminal LPS transfer region (aa 276 ‑ 477) (26, 27). There are two potential splice variants. One shows a four aa substitution for aa 154 - 157 coupled to an Ala substitution for aa 266 ‑ 270, while another contains a seven aa substitution for aa 468 ‑ 481. Mature human LBP shares 68% and 69% aa identity with mouse and rat LBP, respectively (14, 22).

References

  1. Beamer, L.J. et al. (1998) Protein Sci. 7:906.
  2. Kirschning, C.J. et al. (1997) Genomics 46:416.
  3. Schroder, N.W.J. & R.R. Schumann (2005) J. Endotoxin Res. 11:237.
  4. Miyake, K. (2006) J. Endotoxin Res. 12:195.
  5. Grube, B.J. et al. (1994) J. Biol. Chem. 269:8477.
  6. Ren, L. et al. (2004) J. Periodont. Res. 39:242.
  7. Hansen, G.H. et al. (2009) Histochem. Cell Biol. 131:727.
  8. Dentener, M.A. et al. (2000) Am. J. Respir. Cell Mol. Biol. 23:146.
  9. Blais, D.R. et al. (2005) Invest. Ophthalmol. Vis. Sci. 46:4235.
  10. Malm, J. et al. (2005) J. Reprod. Immunol. 66:33.
  11. Schumann, R.R. et al. (1996) Mol. Cell. Biol. 16:3490.
  12. Weber, J.R. et. al. (2003) Immunity 19:269.
  13. Schroder, N.W.J. et al. (2004) J. Immunol. 173:2683.
  14. Su, G.L. et al. (1994) J. Immunol. 153:743.
  15. Schroder, N.W.J. et al. (2003) J. Biol. Chem. 178:15587.
  16. Wright, S.D. et al. (1989) J. Exp. Med. 170:1231.
  17. Hallatschek, W. et al. (2004) Eur. J. Immunol. 34:1441.
  18. Schumann, R.R. & E. Latz (2000) Chem. Immunol. 74:42.
  19. Mannel, D.N. & B. Echtenacher (2000) Chem. Immunol. 74:141.
  20. Tsukamoto, H. et al. (2010) Int. Immunol. 22:271.
  21. Heinzelmann, M. & H. Bosshart (2005) J. Immunol. 174:2280.
  22. Gallay, P. et al. (1993) Infect. Immun. 61:378.
  23. Levels, J.H.M. et al. (2005) Infect. Immun. 73:2321.
  24. Hubacek, J.A. et al. (1997) Biochem. Biophys. Res. Commun. 236:427.
  25. Thompson, P.A. & R.L. Kitchens (2006) J. Immunol. 177:4880.
  26. Schumann, R.R. et al. (1990) Science 249:1429.
  27. Theofan, G. et al. (1994) J. Immunol. 152:3623.

Long Name

Lipopolysaccharide-binding Protein

Alternate Names

lipopolysaccharide binding protein, lipopolysaccharide-binding protein, LPS-binding protein, MGC22233

Entrez Gene IDs

3929 (Human); 16803 (Mouse)

Gene Symbol

LBP

UniProt

Additional LBP Products

Product Documents for Recombinant Human LBP (Histidine-tagged) Protein

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Human LBP (Histidine-tagged) Protein

For research use only

Loading...
Loading...
Loading...